Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2020
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha TherapyUrs B Hagemann, Katrine Wickstroem, Stefanie Hammer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 1, 2025
Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-upSabine Zitzmann-Kolbe, Yvonne Remde, Ingrid Moen, et al.
British Journal of Cancer|December 8, 2021
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansineVincent Chen, Shigeki Umemura, Yumin Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2021
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer ModelsStefanie Hammer, Andreas Schlicker, Sabine Zitzmann-Kolbe, et al.
Cancer Cell|January 11, 2017
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKTJuliane Paul, Maurice Soujon, Antje M Wengner, et al.
Molecular Cancer Therapeutics|June 26, 2023
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic TherapiesSabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate CancerStefanie Hammer, Urs B Hagemann, Sabine Zitzmann-Kolbe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 27, 2014
First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinomaIrene A Burger, Sabine Zitzmann-Kolbe, Jan Pruim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In VivoGerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Journal for Immunotherapy of Cancer|October 7, 2021
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapyPascale Lejeune, Véronique Cruciani, Axel Berg-Larsen, et al.
Pageof 3